Corresponding Author

Skala Mamand Jawhar

Authors ORCID


Document Type

Research Article


The latest anti-diabetic medication sodium-glucose co-transporter inhibitor along with the lowering of blood glucose has a cardioprotective and reno-protective effect, it has the ability to reduce the development of heart failure and decrease hospitalization in heart failure subjects with and without diabetes. This study was conducted to evaluate the effect of sodium-glucose co-transporter inhibitor dapagliflozin alone and in combination with eplerenone on the aldosterone hormone in the treatment of rats with experimentally induced heart failure


dapagliflozin, eplerenone, heart failure, aldosterone, neurohormonal change.

Publication Date


Included in

Life Sciences Commons